Startseite
Impressum
Datenschutz
 
Volume 37, 29 July 2006 8/2006
 
  NEW ON THE MARKET

Natalizumab (TYSABRI) for multiple sclerosis: renewed clinical testing needed
Renewed approval for the neuroleptic sertindole (SERDOLECT): incomprehensible

 
  THERAPY FROM A CRITICAL VIEWPOINT
 

Intensive insulin therapy for critically ill patients?

 
  a-t READERS' QUESTIONS AND COMMENTS
 

Vasopressin analogue desmopressin (e.g. MINIRIN) for enuresis nocturna?

 
  IN BRIEF
 

Warning on allegedly herbal remedies for impotence

 
  CURRENT ADR NETWORK REPORT
 

Olfactory and taste disturbance with roxithromycin (e.g. RULID) and other macrolides

 
  SIDE EFFECTS
 

Liver damage due to the phytoestrogen containing cimicifuga preparations (e.g. REMIFEMIN)
Priapism associated with withdrawal from sustained-release methylphenidate (e.g. CONCERTA)
Increase of fatal strokes with the osteoporosis-drug raloxifene (EVISTA)

 
© arznei-telegramm 8/2006